Shopping Cart
Remove All
Your shopping cart is currently empty
Inebilizumab(FUT8-KO) is a modified version of inebilizumab that features a knocked-out fucosyltransferase 8 gene (FUT8). This anti-CD19 monoclonal antibody (mAb) exhibits enhanced antibody-dependent cell-mediated cytotoxicity against B cells, making it suitable for research into multiple sclerosis and neuromyelitis optica.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $456 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $1,280 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $1,980 | 2-4 weeks | 2-4 weeks |
| Description | Inebilizumab(FUT8-KO) is a modified version of inebilizumab that features a knocked-out fucosyltransferase 8 gene (FUT8). This anti-CD19 monoclonal antibody (mAb) exhibits enhanced antibody-dependent cell-mediated cytotoxicity against B cells, making it suitable for research into multiple sclerosis and neuromyelitis optica. |
| Storage | -20°C for 1 year | Shipping with blue ice. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.